GLP-1 & MetabolicLimited ResearchResearch OnlyD

ITPP

Myo-inositol trispyrophosphate

Last reviewed . First published . By the PeptIQ team.

Educational and observational reference only. Not medical advice. Community charts may use modeled aggregates when live snapshots are unavailable.

Studies cited
3
Research grade
D
Experience
78

Overall check-ins

Activity
79

Trackers & reports

Typical Dose

Varies by protocol

Route

Injectable / Oral research forms

Cycle

Research protocol-dependent

Storage

Room Temperature

What is ITPP?

Experimental oxygen-delivery/metabolic performance compound tracked in research circles.

Research Indications

Weight LossMost Effective

Clinical trials demonstrate significant body weight reduction with sustained benefit

Blood Sugar ControlMost Effective

Improves glycemic control and A1C levels in type 2 diabetes

Cardiovascular HealthEffective

Associated with reduced cardiovascular events in high-risk patients

Metabolic SyndromeEffective

Addresses multiple components of metabolic syndrome simultaneously

Research Protocols

These are commonly discussed research protocols — not medical advice. Consult a healthcare provider before use.

GoalDoseFrequencyRoute
Starting DoseLow doseOnce weeklySubcutaneous injection
Maintenance DoseTitrated doseOnce weeklySubcutaneous injection

Peptide & Drug Interactions

Always consult your healthcare provider before combining with other compounds. Use our Interaction Checker for reference.

Other GLP-1 Agonists (e.g. Semaglutide + Tirzepatide)Avoid
InsulinMonitor
SulfonylureasMonitor
MetforminCompatible
SGLT2 InhibitorsCompatible
Oral ContraceptivesCaution
Warfarin / Blood ThinnersMonitor
NAD+Compatible

How to Reconstitute & Inject

Use bacteriostatic (BAC) water only. Avoid saline — may cause precipitation. Refrigerate and use within 28 days.

  1. 1

    Remove ITPP vial from refrigeration and allow to reach room temperature (15–20 minutes)

  2. 2

    Clean vial top with alcohol swab and allow to air dry completely

  3. 3

    Using a sterile syringe, draw the calculated volume of bacteriostatic water (BAC water)

  4. 4

    Inject BAC water slowly down the side of the vial — do not aim directly at the powder

  5. 5

    Gently swirl in circular motions — DO NOT shake vigorously as this degrades the peptide

  6. 6

    Allow 2–3 minutes for full dissolution — solution should be clear and colorless

  7. 7

    Draw calculated dose into an insulin syringe for subcutaneous injection

  8. 8

    Inject into abdomen, thigh, or upper arm. Rotate injection sites to prevent lipodystrophy

  9. 9

    Store reconstituted solution refrigerated (2–8°C) and use within 28 days

What to Expect

Week 1–2

Initial appetite suppression may begin. Mild GI effects (nausea, fullness) as your body adapts.

Week 2–4

Noticeable reduction in food cravings and portion sizes. Early weight changes begin.

Week 4–8

Significant appetite control and steady weight loss. Improved blood sugar if applicable.

Week 8–16

Substantial weight reduction and enhanced energy. Metabolic markers begin improving.

Week 16–24

Major weight loss milestone with cardiovascular benefits and improved lipid profiles.

Week 24+

Maximum clinical efficacy. Comprehensive metabolic improvements and sustained benefits.

Side Effects & Safety

  • Nausea (most common, typically dose-dependent and transient)
  • Diarrhea or constipation during dose escalation
  • Vomiting, especially when starting or increasing dose
  • Reduced appetite and early satiety
  • Injection site reactions (redness, bruising)
  • Fatigue, particularly in early weeks
  • Rare: Pancreatitis — discontinue immediately with severe abdominal pain
  • Rare: Thyroid C-cell effects (contraindicated with MEN2 or thyroid cancer history)

FDA Status & Regulatory Info

Research Only

Experimental oxygen-delivery/metabolic performance compound tracked in research circles.

Rx Required: No
503A Ban: No
Telehealth: N/A
Full FDA Status Tracker

Frequently Asked Questions

Community-reported data

The information below reflects self-reported experiences from PeptIQ app users. It is not clinical evidence and should not replace professional medical advice.

What 763 users report

Observational self-reports (modeled when live data is unavailable). Not clinical outcomes.

763 community reports

Overall experience

From check-in ratings — separate from side effects logged below. Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.

Favorable 67% · Mixed 18% · Unfavorable overall 15%

Most reported benefits

Benefits users selected when logging a favorable or mixed check-in.

Skin appearance
38
Appetite control
150
Energy
51
Mood
106
Focus
91

Most logged side effects

Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.

Headache
134
GI discomfort
49
Dizziness
16
Fatigue
102
Nausea
90

Self-reported dose per injection

Median bucket: 0.6–1 mg · Most common: 0.6–1 mg

Reports span 0.05 to ≥ 5 mg (open-ended top bucket)

0.05–0.1 mg
3
0.1–0.2 mg
6
0.2–0.4 mg
11
0.4–0.6 mg
22
0.6–1 mg
31
1–2 mg
25
2–3 mg
18
3–5 mg
11
5+ mg
4

Anonymized self-reports from PeptIQ users — not prescribing guidance. Buckets group similar logged amounts; open-ended top buckets mean “at least” that dose.

Common discussion topics

timing47stacking25side effects33itpp21

How repeat users are trending

Among repeat reporters, 62% said they felt similar to their last entry, 29% more positive, and 17% more negative.

Overall, repeat reporters leaned more positive than their previous entry.

Median gap between entries: 15 days · Based on 168 repeat reporters

Share Your Experience

Rate ITPP in the PeptIQ app and help the community make informed decisions.

Research References (2)

Cited PubMed, trial registry, and label sources for education only. We do not control third-party content.

  1. PubMed

    Phase Ib dose-escalation study of the hypoxia-modifier Myo-inositol trispyrophosphate in patients with hepatopancreatobiliary tumors

    Schneider MA, Linecker M, Fritsch R, et al. Nat Commun. 2021

    Source
    Wiki study page →
  2. ClinicalTrials.gov

    Effects of OXY111A (Myo-inositol trispyrophosphate) in Hepato-Pancreato-Biliary Neoplasms (NCT02528526)

    ClinicalTrials.gov. Clinical trial registry. 2015

    Source
    Wiki study page →

Wiki tools

Observational indexes and compare views for ITPP.

Educational information only

This page is for educational reference. It is not medical or legal advice. PeptIQ does not sell peptides or list vendors. Consult the FDA and a licensed healthcare professional for current regulations and individualized guidance.

PeptIQ app

Log your ITPP protocol in PeptIQ

Turn this ITPP guide into a living protocol — doses, vials, and history in one place.

Track ITPPOpen web app

iOS, Android, and web

Ask PeptIQ

Two taps on our guided quiz, then keep going in iMessage with sources — not Instagram screenshots.

Start the quizOr try Peptide X Quiz →

Quick Facts

Route
Injectable / Oral research forms
Availability
Research only
Rx Required
No
503A Ban
No
Browse peptide education

Talk with a clinician

PeptIQ is education only. We do not sell peptides or list vendors. Discuss ITPP with a licensed healthcare provider — not medical advice, not a prescription.

Download PeptIQ

Wiki tools

Observational indexes and compare views for ITPP.